PE20151871A1 - Anticuerpos de receptor anti-glucagon y metodos de uso de los mismos - Google Patents
Anticuerpos de receptor anti-glucagon y metodos de uso de los mismosInfo
- Publication number
- PE20151871A1 PE20151871A1 PE2015002374A PE2015002374A PE20151871A1 PE 20151871 A1 PE20151871 A1 PE 20151871A1 PE 2015002374 A PE2015002374 A PE 2015002374A PE 2015002374 A PE2015002374 A PE 2015002374A PE 20151871 A1 PE20151871 A1 PE 20151871A1
- Authority
- PE
- Peru
- Prior art keywords
- glucagon receptor
- hiperglucemia
- antibodies
- methods
- glucose
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
LA INVENCION SE REFIERE A ANTICUERPOS ANTAGONISTAS AISLADOS QUE SE ENLAZAN ESPECIFICAMENTE AL RECEPTOR DE GLUCAGON Y EVITAN O REDUCEN EL EFECTO BIOLOGICO DEL MISMO. SE REFIERE TAMBIEN A COMPOSICIONES QUE COMPRENDE DICHOS ANTICUERPOS. LOS ANTICUERPOS DE LA INVENCION SON TERAPEUTICAMENTE UTILES PARA REDUCIR LOS NIVELES DE GLUCOSA EN LA SANGRE, POR LO CUAL SE PUEDEN EMPLEAR EN LA TERAPIA DE PADECIMIENTOS RELACIONADOS CON LA GLUCOSA, QUE INCLUYEN DIABETES, HIPERGLUCEMIA, HIPERINSULINEMIA, GLUCOSA EN AYUNAS DETERIORADA, TOLERANCIA DETERIORADA A LA GLUCOSA, DISLIPIDEMIA O SINDROME METABOLICO
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361820604P | 2013-05-07 | 2013-05-07 | |
US201461981115P | 2014-04-17 | 2014-04-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20151871A1 true PE20151871A1 (es) | 2015-12-24 |
Family
ID=50884431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2015002374A PE20151871A1 (es) | 2013-05-07 | 2014-05-02 | Anticuerpos de receptor anti-glucagon y metodos de uso de los mismos |
Country Status (15)
Country | Link |
---|---|
US (2) | US9248189B2 (es) |
EP (1) | EP2994489A2 (es) |
JP (1) | JP2016520058A (es) |
KR (1) | KR20160005749A (es) |
CN (1) | CN105189560A (es) |
AU (1) | AU2014264295A1 (es) |
CA (1) | CA2911412A1 (es) |
HK (1) | HK1218421A1 (es) |
MX (1) | MX2015015339A (es) |
PE (1) | PE20151871A1 (es) |
PH (1) | PH12015502547A1 (es) |
RU (1) | RU2015147721A (es) |
SG (1) | SG11201508264UA (es) |
TW (2) | TW201446803A (es) |
WO (1) | WO2014181229A2 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10610504B2 (en) * | 2014-12-23 | 2020-04-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Alpha-cell re-generation combined with conversion to beta cells |
MX2017012694A (es) * | 2015-04-02 | 2018-03-07 | Remb Biotherapeutics Inc | Metodos para tratar la obesidad y la enfermedad del higado graso no alcoholica o esteatohepatitis no alcoholica utilizando anticuerpos antagonistas del receptor de glucagon. |
WO2017055966A1 (en) | 2015-10-01 | 2017-04-06 | Pfizer Inc. | Low viscosity antibody compositions |
US20190062441A1 (en) * | 2015-10-07 | 2019-02-28 | Remd Biotherapeutics, Inc. | Methods For Treating Rare Genetic Disorders Using Glucagon Receptor Antagonistic Antibodies |
US20190002577A1 (en) * | 2016-01-04 | 2019-01-03 | Remd Biotherapeutics, Inc. | Methods Of Treating Type 2 Diabetes Mellitus Using Glucagon Receptor Antagonistic Antibodies |
WO2018005445A1 (en) | 2016-06-27 | 2018-01-04 | The Broad Institute, Inc. | Compositions and methods for detecting and treating diabetes |
JP7038707B2 (ja) * | 2016-06-27 | 2022-03-18 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 代謝障害の治療に有用な化合物 |
MA46089A (fr) | 2016-08-30 | 2019-07-10 | Regeneron Pharma | Procédés de traitement de la résistance à l'insuline grave par interférence avec la signalisation du récepteur du glucagon |
EP3529278A1 (en) * | 2016-10-20 | 2019-08-28 | Regeneron Pharmaceuticals, Inc. | Methods of lowering blood glucose levels |
MX2019008722A (es) * | 2017-01-27 | 2019-10-02 | Ngm Biopharmaceuticals Inc | Proteínas de unión al receptor de glucagón y métodos para usarlas. |
CN110357959B (zh) * | 2018-04-10 | 2023-02-28 | 鸿运华宁(杭州)生物医药有限公司 | Gcgr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用 |
WO2020023847A1 (en) | 2018-07-27 | 2020-01-30 | Ngm Biopharmaceuticals, Inc. | Use of glucagon receptor antagonists with immunotherapeutic agent |
MX2021007444A (es) | 2018-12-21 | 2021-08-05 | Jiangsu Hengrui Medicine Co | Proteina biespecifica. |
CN110898225A (zh) * | 2019-12-23 | 2020-03-24 | 黑龙江中医药大学 | mTOR/S6K1及MAPK信号通路抑制在胰岛素抵抗改善中的应用 |
CN113045657B (zh) * | 2019-12-26 | 2022-06-07 | 杭州济元基因科技有限公司 | 一种人源化抗人bcma单克隆抗体及其car-t细胞 |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
WO1995013796A1 (en) | 1993-11-16 | 1995-05-26 | Depotech Corporation | Vesicles with controlled release of actives |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
EP0832980B1 (en) | 1989-01-23 | 2002-06-19 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
WO1990011092A1 (en) | 1989-03-21 | 1990-10-04 | Vical, Inc. | Expression of exogenous polynucleotide sequences in a vertebrate |
WO1991000360A1 (en) | 1989-06-29 | 1991-01-10 | Medarex, Inc. | Bispecific reagents for aids therapy |
WO1991002805A2 (en) | 1989-08-18 | 1991-03-07 | Viagene, Inc. | Recombinant retroviruses delivering vector constructs to target cells |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
NZ237464A (en) | 1990-03-21 | 1995-02-24 | Depotech Corp | Liposomes with at least two separate chambers encapsulating two separate biologically active substances |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
JPH06507398A (ja) | 1991-05-14 | 1994-08-25 | リプリジェン コーポレーション | Hiv感染治療のための異種複合抗体 |
GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
WO1993003769A1 (en) | 1991-08-20 | 1993-03-04 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES | Adenovirus mediated transfer of genes to the gastrointestinal tract |
AU669124B2 (en) | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
DK0605522T3 (da) | 1991-09-23 | 2000-01-17 | Medical Res Council | Fremgangsmåde til fremstilling af humaniserede antistoffer |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
WO1993010260A1 (en) | 1991-11-21 | 1993-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1993025234A1 (en) | 1992-06-08 | 1993-12-23 | The Regents Of The University Of California | Methods and compositions for targeting specific tissue |
JPH09507741A (ja) | 1992-06-10 | 1997-08-12 | アメリカ合衆国 | ヒト血清による不活性化に耐性のあるベクター粒子 |
GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
EP0656064B1 (en) | 1992-08-17 | 1997-03-05 | Genentech, Inc. | Bispecific immunoadhesins |
WO1994005789A1 (en) | 1992-08-28 | 1994-03-17 | Zymogenetics, Inc. | Glucagon receptors |
EP0673431A1 (en) | 1992-12-03 | 1995-09-27 | Genzyme Corporation | Gene therapy for cystic fibrosis |
US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
PT695169E (pt) | 1993-04-22 | 2003-04-30 | Skyepharma Inc | Lipossomas multivesiculares de ciclodextrina encapsulando compostos farmacologicos e metodos para a sua utilizacao |
JP3532566B2 (ja) | 1993-06-24 | 2004-05-31 | エル. グラハム,フランク | 遺伝子治療のためのアデノウイルスベクター |
DE69435233D1 (de) | 1993-09-15 | 2009-10-08 | Novartis Vaccines & Diagnostic | Rekombinante Alphavirus Vektoren |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
ATE437232T1 (de) | 1993-10-25 | 2009-08-15 | Canji Inc | Rekombinanter adenoviren-vektor und verfahren zur verwendung |
US6436908B1 (en) | 1995-05-30 | 2002-08-20 | Duke University | Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function |
ATE381624T1 (de) | 1994-05-09 | 2008-01-15 | Oxford Biomedica Ltd | Retrovirale vektoren mit verminderter rekombinationsrate |
AU4594996A (en) | 1994-11-30 | 1996-06-19 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
DE69739286D1 (de) | 1996-05-06 | 2009-04-16 | Oxford Biomedica Ltd | Rekombinationsunfähige retrovirale vektoren |
US6376471B1 (en) | 1997-10-10 | 2002-04-23 | Johns Hopkins University | Gene delivery compositions and methods |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
WO2000053211A2 (en) | 1999-03-09 | 2000-09-14 | University Of Southern California | Method of promoting myocyte proliferation and myocardial tissue repair |
NZ540730A (en) | 2002-12-24 | 2010-09-30 | Rinat Neuroscience Corp | Anti-NGF antibodies and methods using same |
AU2006236508B2 (en) | 2005-04-15 | 2012-02-02 | Precision Biologics, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
CL2007002668A1 (es) | 2006-09-20 | 2008-05-09 | Amgen Inc | Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. |
PE20091674A1 (es) * | 2008-03-27 | 2009-11-04 | Lilly Co Eli | Antagonistas del receptor de glucagon |
CA2772590C (en) * | 2009-09-08 | 2017-01-03 | Neopharm Co., Ltd. | Antibodies against glucagon receptor and their use |
JO3756B1 (ar) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
-
2014
- 2014-05-02 KR KR1020157034642A patent/KR20160005749A/ko not_active Application Discontinuation
- 2014-05-02 PE PE2015002374A patent/PE20151871A1/es not_active Application Discontinuation
- 2014-05-02 EP EP14727928.5A patent/EP2994489A2/en not_active Withdrawn
- 2014-05-02 CA CA2911412A patent/CA2911412A1/en not_active Abandoned
- 2014-05-02 SG SG11201508264UA patent/SG11201508264UA/en unknown
- 2014-05-02 CN CN201480026244.5A patent/CN105189560A/zh active Pending
- 2014-05-02 JP JP2016512455A patent/JP2016520058A/ja active Pending
- 2014-05-02 US US14/268,933 patent/US9248189B2/en not_active Expired - Fee Related
- 2014-05-02 MX MX2015015339A patent/MX2015015339A/es unknown
- 2014-05-02 RU RU2015147721A patent/RU2015147721A/ru not_active Application Discontinuation
- 2014-05-02 WO PCT/IB2014/061166 patent/WO2014181229A2/en active Application Filing
- 2014-05-02 AU AU2014264295A patent/AU2014264295A1/en not_active Abandoned
- 2014-05-06 TW TW103116190A patent/TW201446803A/zh unknown
- 2014-05-06 TW TW105131941A patent/TW201702274A/zh unknown
-
2015
- 2015-11-06 PH PH12015502547A patent/PH12015502547A1/en unknown
- 2015-12-21 US US14/976,301 patent/US20160311912A1/en not_active Abandoned
-
2016
- 2016-06-03 HK HK16106367.4A patent/HK1218421A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
PH12015502547A1 (en) | 2016-02-22 |
SG11201508264UA (en) | 2015-11-27 |
JP2016520058A (ja) | 2016-07-11 |
EP2994489A2 (en) | 2016-03-16 |
CA2911412A1 (en) | 2014-11-13 |
TW201702274A (zh) | 2017-01-16 |
TW201446803A (zh) | 2014-12-16 |
MX2015015339A (es) | 2016-07-15 |
HK1218421A1 (zh) | 2017-02-17 |
RU2015147721A (ru) | 2017-06-15 |
WO2014181229A2 (en) | 2014-11-13 |
WO2014181229A3 (en) | 2015-04-16 |
US20160311912A1 (en) | 2016-10-27 |
KR20160005749A (ko) | 2016-01-15 |
AU2014264295A1 (en) | 2015-10-29 |
US20140335091A1 (en) | 2014-11-13 |
US9248189B2 (en) | 2016-02-02 |
CN105189560A (zh) | 2015-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20151871A1 (es) | Anticuerpos de receptor anti-glucagon y metodos de uso de los mismos | |
CU20170045A7 (es) | Anticuerpos agonistas de anti-gitr y composiciones de los mismos | |
CL2017000651A1 (es) | Anticuerpos anti-glucagón y sus usos | |
CY1121389T1 (el) | Αντισωματα που δεσμευονται ειδικα με την α-τοξινη toy staphylococcus aureus και μεθοδοι χρησης | |
BR112019007100A2 (pt) | composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão | |
PH12018500714A1 (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
CO2017005650A2 (es) | Anticuerpos anti-interleucina-33 | |
EA201791485A1 (ru) | Анти-cd47-антитела и их применения | |
CL2015002654A1 (es) | Polipéptidos de il-22 y proteínas de fusión de il-22 fc y métodos de uso | |
CL2014003465A1 (es) | Anticuerpo que se une al receptor del factor de crecimiento epidérmico humano dimérico (hegfr) ; composición farmacéutica que lo comprende; y uso para tratar el cáncer. | |
AR102712A1 (es) | Agonistas parciales del receptor de insulina | |
CL2013002053A1 (es) | Compuestos derivados de heterociclicos, antagonistas del receptor de glucagon; composicion farmaceutica que lo comprende y su uso en el tratamiento de diabetes y enfermedades metabolicas. pct | |
EA201391764A1 (ru) | Агонисты рецептора glp-1/глюкагона длительного действия | |
EA201591611A1 (ru) | Конъюгаты антитело-лекарственное средство | |
ECSP17034845A (es) | Conjugados de anticuerpo- farmaco | |
DOP2015000108A (es) | Compuestos de pirrolopirimidina como inhibidores de quinasas | |
CL2016002004A1 (es) | Anticuerpos anti-jagged1 y métodos de uso | |
UY36179A (es) | Derivados de exendina-4 como agonistas selectivos del receptor de glucagón | |
CL2014003462A1 (es) | Uso de compuestos aminotriazolopiridinas sustituidos, en el tratamiento de afecciones inflamatorias, autoinmunitarias, proliferativas, alergias, rechazo de trasplantes, entre otras; composicion farmaceutica que los comprende; combinacion farmaceutica. | |
PE20170256A1 (es) | Proteinas de union y sus metodos de uso | |
UY35417A (es) | Anticuerpos dirigidos contra il-33 y sus usos. | |
EA201590993A1 (ru) | Гетеродимерные иммуноглобулины | |
CO2017002160A2 (es) | Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias | |
CR20130632A (es) | El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico | |
EA201590412A1 (ru) | Композиции антител и их применения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |